Pin1, endothelial nitric oxide synthase, and amyloid-β form a feedback signaling loop involved in the pathogenesis of Alzheimer's disease, hypertension, and cerebral amyloid angiopathy

Medical Hypotheses

Volumn 82, Issue 2, 2014, Pages 145-150

  Wang, Jing Zhang ^a   Zhu, Wang Dong ^a   Xu, Zhong Xin ^a   Du, Wen Tao ^a   Zhang, Hong Yan ^a   Sun, Xue Wen ^a   Wang, Xiao Hua ^a  

^a HEBEI UNIVERSITY OF ENGINEERING   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PEPTIDYLPROLYL ISOMERASE PIN1;

ALZHEIMER DISEASE; ARTICLE; DISEASE COURSE; FEEDBACK SYSTEM; HUMAN; HYPERTENSION; NONHUMAN; PATHOGENESIS; SIGNAL TRANSDUCTION; VASCULAR AMYLOIDOSIS;

AD; ALZHEIMER'S DISEASE; AMYLOID-Β (BETA); AΒ; CAA; CEREBRAL AMYLOID ANGIOPATHY; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENOS; HTN; HYPERTENSION;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD PRESSURE; CEREBRAL AMYLOID ANGIOPATHY; HUMANS; HYPERTENSION; MODELS, THEORETICAL; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDYLPROLYL ISOMERASE; SIGNAL TRANSDUCTION;

EID: 84892366118     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.11.023     Document Type: Article

References (84)

1. Smith E.E., Greenberg S.M. Beta-amyloid, blood vessels, and brain function. Stroke 2009, 40:2601-2606.
2. Zharikov S.I., Swenson E.R., Lanaspa M., Block E.R., Patel J.M., Johnson R.J. Could uric acid be a modifiable risk factor in subjects with pulmonary hypertension?. Med Hypotheses 2010, 74:1069-1074.
3. Li J.S., Yao Z.X. Modulation of FGF receptor signaling as an intervention and potential therapy for myelin breakdown in Alzheimer's disease. Med Hypotheses 2013, 80:341-344.
4. Werring D.J., Gregoire S.M., Cipolotti L. Cerebral microbleeds and vascular cognitive impairment. J Neurol Sci 2010, 299:131-135.
5. Charidimou A., Werring D.J. Cerebral microbleeds and cognition in cerebrovascular disease: an update. J Neurol Sci 2012, 322:50-55.
6. Gorelick P.B., Scuteri A., Black S.E., et al. Vascular contributions to cognitive impairment and dementia a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42:2672-2713.
7. Serino S., Riva G. Getting lost in Alzheimer's disease: a break in the mental frame syncing. Med Hypotheses 2013, 80:416-421.
8. Elias M.F., Davey A. Midlife blood pressure, amyloid-beta, and risk for Alzheimer disease one more reason to treat hypertension. Hypertension 2012, 59:771-772.
9. Steenland K., Levey A.I., Goldstein F.C. Hypertension and Alzheimer disease is there a link?. Epidemiology 2012, 23:176-177.
10. Kuyumcu M.E., Yesil Y., Ozturk Z.A., et al. Alzheimer's disease is associated with a low prevalence of hypertension. Dement Geriatr Cogn 2012, 33:6-10.
11. Inzelberg R., Massarwa M., Schechtman E., et al. Hypertension increases the probability of Alzheimer's disease and of being cognitively impaired not demented in wadi ara villages: a door-to-door population study. Neurology 2009, 72:A480.
12. Israeli-Korn S.D., Masarwa M., Schechtman E., et al. Hypertension increases the probability of Alzheimer's disease and of mild cognitive impairment in an arab community in Northern Israel. Neuroepidemiology 2010, 34:99-105.
13. Salkovic-Petrisic M., Osmanovic-Barilar J., Bruckner M.K., Hoyer S., Arendt T., Riederer P. Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study. J Neural Transm 2011, 118:765-772.
14. Ringman J.M., Sachs M., Beigi M., Lu P.H., Saver J.L., Vinters H.V. Clinical predictors of severe cerebral amyloid angiopathy in Alzheimer's disease patients. Neurology 2011, 76:A662.
15. Tian J., Shi J., Smallman R., Iwatsubo T., Mann D.M.A. Relationships in Alzheimer's disease between the extent of A beta deposition in cerebral blood vessel walls, as cerebral amyloid angiopathy, and the amount of cerebrovascular smooth muscle cells and collagen. Neuropathol Appl Neurobiol 2006, 32:332-340.
16. De Reuck J., Deramecourt V., Cordonnier C., Leys D., Maurage C.A., Pasquier F. The impact of cerebral amyloid angiopathy on the occurrence of cerebrovascular lesions in demented patients with Alzheimer features: a neuropathological study. Eur J Neurol 2011, 18:913-918.
17. Vasileyko V, Passos GF, Quiring D, et al. Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. In: DelZoppo GJ, Gorelick PB, Eisert W, editors. Innate inflammation and stroke, New York: Academy of Sciences; 2010. p. 58-70.
18. Zhang W.W. Pathological changes on vascular smooth muscle cells in the human brain of cerebral amyloid angiopathy and hypertension. Stroke 2008, 39:713-714.
19. Lee S.H., Kim S.M., Kim N., Yoon B.W., Roh J.K. Cortico-subcortical distribution of microbleeds is different between hypertension and cerebral amyloid angiopathy. J Neurol Sci 2007, 258:111-114.
20. Shah N.S., Vidal J.S., Masaki K., et al. Midlife blood pressure, plasma beta-amyloid, and the risk for Alzheimer disease: the Honolulu Asia aging study. Hypertension 2012, 59:780-786.
21. Nakata-Kudo Y., Mizuno T., Yamada K., et al. Microbleeds in Alzheimer disease are more related to cerebral amyloid angiopathy than cerebrovascular disease. Dement Geriatr Cogn 2006, 22:8-14.
22. Sierra C. Cerebral small vessel disease, cognitive impairment and vascular dementia. Panminerva Med 2012, 54:179-187.
23. Cherubini A., Lowenthal D.T., Paran E., Mecocci P., Williams L.S., Senin U. Hypertension and cognitive function in the elderly. Dm-Dis Mon 2010, 56:106-147.
24. Duan Y., Dong S., Gu F., Hu Y., Zhao Z. Advances in the pathogenesis of Alzheimer's disease: focusing on tau-mediated neurodegeneration. Transl Neurodegener 2012, 1:24.
25. Pastorino L., Lu K.P. Pathogenic mechanisms in Alzheimer's disease. Eur J Pharmacol 2006, 545:29-38.
26. Iadecola C., Park L., Capone C. Threats to the mind aging, amyloid, and hypertension. Stroke 2009, 40:S40-S44.
27. Liou Y.C., Zhou X.Z., Lu K.P. Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci 2011, 36:501-514.
28. Lee T.H., Pastorino L., Lu K.P. Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease. Expert Rev Mol Med 2011, 13:e21.
29. Wang J.Z., Li S.R., Li Y.L., et al. Could Pin1 help us conquer essential hypertension at an earlier stage? A promising early-diagnostic biomarker and its therapeutic implications for the disease. Med Hypotheses 2013, 81:931-935.
30. Pastorino L., Sun A., Lu P.J., et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 2006, 440:528-534.
31. Tamayev R., Zhou D., D'Adamio L. The interactome of the amyloid beta precursor protein family members is shaped by phosphorylation of their intracellular domains. Mol Neurodegener 2009, 4:28.
32. Driver J.A. Understanding the link between cancer and neurodegeneration. J Geriatr Oncol 2012, 3:58-67.
33. Erol A. Pin1 as a protector of vascular endothelial homeostasis. Hypertension 2012, 59:e14.
34. Chiasson V.L., Munshi N., Chatterjee P., Young K.J., Mitchell B.M. Pin1 deficiency causes endothelial dysfunction and hypertension. Hypertension 2011, 58:431-438.
35. Ruan L., Torres C.M., Qian J., et al. Pin1 prolyl isomerase regulates endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol 2011, 31:392-398.
36. Andresen J., Shafi N.I., Bryan R.M. Endothelial influences on cerebrovascular tone. J Appl Physiol 2006, 100:318-327.
37. Ferlazzo N., Gorgone G., Caccamo D., et al. The 894G>T (Glu298Asp) variant in the endothelial NOS gene and MTHFR polymorphisms influence homocysteine levels in patients with cognitive decline. Neuromolecular Med 2011, 13:167-174.
38. Austin S.A., Santhanam A.V., Katusic Z.S. Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ Res 2010, 107:1498-1502.
39. Austin S.A., D'Uscio L.V., Katusic Z.S. Supplementation of nitric oxide attenuates A beta PP and BACE1 protein in cerebral microcirculation of eNOS-deficient mice. J Alzheimers Dis 2013, 33:29-33.
40. Toda N. Age-related changes in endothelial function and blood flow regulation. Pharmacol Ther 2012, 133:159-176.
41. Toda N., Okamura T. Cerebral blood flow regulation by nitric oxide in Alzheimer's disease. J Alzheimers Dis 2012, 32:569-578.
42. Weller R.O., Subash M., Preston S.D., Mazanti I., Carare R.O. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008, 18:253-266.
43. Misiti F., Carelli-Alinovi C., Sampaolese B., Giardina B. Beta-amyloid decreases detectable endothelial nitric oxide synthase in human erythrocytes: a role for membrane acetylcholinesterase. Cell Biochem Funct 2012, 30:474-479.
44. Chisari M., Merlo S., Sortino M.A., Salomone S. Long-term incubation with beta-amyloid peptides impairs endothelium-dependent vasodilatation in isolated rat basilar artery. Pharmacol Res 2010, 61:157-161.
45. Niwa K., Carlson G.A., Iadecola C. Exogenous A beta 1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab 2000, 20:1659-1668.
46. Townsend KP, Obregon D, Quadros A, et al. Proinflammatory and vasoactive effects of A beta in the cerebrovasculature. In: DeLaTorre JC, Kalaria R, Nakajima K, Nagata K, editors. Alzheimer's disease: vascular etiology and pathology, New York: Academy of Sciences; 2002. p. 65-76.
47. Gilbert B.J. The role of amyloid beta in the pathogenesis of Alzheimer's disease. J Clin Pathol 2013, 66:362-366.
48. Biffi A., Shulman J.M., Jagiella J.M., et al. Genetic variation at CR1 increases risk of cerebral amyloid angiopathy. Neurology 2012, 78:334-341.
49. Vinters H.V. Cerebral amyloid angiopathy - a critical-review. Stroke 1987, 18:311-324.
50. Vinters H.V., Gilbert J.J. Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 1983, 14:924-928.
51. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010, 9:689-701.
52. Grinberg L.T., Korczyn A.D., Heinsen H. Cerebral amyloid angiopathy impact on endothelium. Exp Gerontol 2012, 47:838-842.
53. Vinters H.V., Wang Z.Z., Secor D.L. Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol 1996, 6:179-195.
54. Loitfelder M., Seiler S., Schwingenschuh P., Schmidt R. Cerebral microbleeds: a review. Panminerva Med 2012, 54:149-160.
55. Cordonnier C. Brain microbleeds: more evidence, but still a clinical dilemma. Curr Opin Neurol 2011, 24:69-74.
56. Lee S.H., Bae H.J., Yoon B.W., Kim H., Kim D.E., Roh J.K. Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging - analysis of risk factors for multifocal signal loss lesions. Stroke 2002, 33:2845-2849.
57. Roob G., Fazekas F. Magnetic resonance imaging of cerebral microbleeds. Curr Opin Neurol 2000, 13:69-73.
58. Roob G., Lechner A., Schmidt R., Flooh E., Hartung H.P., Fazekas F. Frequency and location of microbleeds in patients with primary intracerebral hemorrhage. Stroke 2000, 31:2665-2669.
59. Li J., Cun Y., Tang W.R., et al. Association of eNOS gene polymorphisms with essential hypertension in the Han population in southwestern China. Genet Mol Res 2011, 10:2202-2212.
60. Wang H.-Y., Bakshi K., Frankfurt M., et al. Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A. J Neurosci 2012, 32:9773-9784.
61. Wang J.Z., Zhang Y.H., Sun X.W., et al. Focusing on the structure and the function of Pin1: new insights into the opposite effects of fever on cancers and Alzheimer's disease. Med Hypotheses 2013, 81:282-284.
62. Lu K.P., Hanes S.D., Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 1996, 380:544-547.
63. Segat L., Pontillo A., Annoni G., et al. PIN1 promoter polymorphisms are associated with Alzheimer's disease. Neurobiol Aging 2007, 28:69-74.
64. Ma S.L., Tang N.L., Tam C.W., et al. A PIN1 polymorphism that prevents its suppression by AP4 associates with delayed onset of Alzheimer's disease. Neurobiol Aging 2012, 33:804-813.
65. Jeynes B., Provias J. Significant negative correlations between capillary expressed eNOS and Alzheimer lesion burden. Neurosci Lett 2009, 463:244-248.
66. Malinski T. Nitric oxide and nitroxidative stress in Alzheimer's disease. J Alzheimers Dis 2007, 11:207-218.
67. Men C., Tang K., Lin G., Li J., Zhan Y. ENOS-G894T polymorphism is a risk factor for essential hypertension in China. Indian J Biochem Biophys 2011, 48:154-157.
68. Aliev G., Palacios H.H., Lipsitt A.E., et al. Nitric oxide as an initiator of brain lesions during the development of Alzheimer disease. Neurotox Res 2009, 16:293-305.
69. Ufnal M. Essential hypertension - is erroneous receptor output to blame?. Med Hypotheses 2012, 78:454-458.
70. Rosales-Mendoza S. Can a plant-based vaccine treat hypertension?. Med Hypotheses 2012, 79:555-559.
71. Fox M.O.B., Gutierrez E.B. Role of the glomerular-tubular imbalance with tubular predominance in the arterial hypertension pathophysiology. Med Hypotheses 2013, 81:397-399.
72. Casserly I., Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 2004, 363:1139-1146.
73. Knopman D.S., Mosley T.H., Catellier D.J., Sharrett A.R. Atherosclerosis Risk C. Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort. Neurology 2005, 65:876-881.
74. Lakhanpal J.R., Domanski M.J. Hypothesis: catheter-based renal sympathetic denervation should be the initial therapy for essential hypertension. Med Hypotheses 2012, 78:482-484.
75. Brenner S. Aluminum may mediate Alzheimer's disease through liver toxicity, with aberrant hepatic synthesis of ceruloplasmin and ATPase7B, the resultant excess free copper causing brain oxidation, beta-amyloid aggregation and Alzheimer disease. Med Hypotheses 2013, 80:326-327.
76. Nicoll J.A.R., Yamada M., Frackowiak J., Mazur-Kolecka B., Weller R.O. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease Pro-CAA position statement. Neurobiol Aging 2004, 25:589-597.
77. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005, 28:202-208.
78. Liu T.Z., Huang Y.C., Likhotvorik R.I., Keshvara L., Hoyt D.G. Protein never in mitosis gene A interacting-1 (PIN1) regulates degradation of inducible nitric oxide synthase in endothelial cells. Am J Physiol Cell Physiol 2008, 295:C819-C827.
79. Liu T., Schneider R.A., Hoyt D.G. Calpastatin is regulated by protein never in mitosis gene A interacting-1 (PIN1) in endothelial cells. Biochem Biophys Res Commun 2011, 414:581-586.
80. Duron E., Rigaud A.S., Dubail D., et al. Effects of antihypertensive therapy on cognitive decline in Alzheimer's disease. Am J Hypertens 2009, 22:1020-1024.
81. Yasar S., Xia J., Yao W., et al. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo evaluation of memory study. Neurology 2013, 81:896-903.
82. Duron E., Hanon O. Antihypertensive treatments, cognitive decline, and dementia. J Alzheimers Dis 2010, 20:903-914.
83. Johnson M.L., Parikh N., Kunik M.E., et al. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimers Demen 2012, 8:437-444.
84. Vitale C., Iellamo F., Volterrani M. Revival of beta-blockers in arterial hypertension. Int J Cardiol 2013, 163:108.